Press Release Aug 30 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for its Scopolamine Transdermal System. This product is designed to prevent nausea and vomiting related to anesthesia, narcotic pain medications, and motion sickness. The approval marks the fifth ANDA approval for Zydus in its transdermal portfolio, showcasing its manufacturing capabilities in complex drug delivery systems. The Scopolamine Transdermal System will be produced at Zydus's facility in Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Aug 27 2024
- Press Release Aug 23 2024
- Press Release Aug 09 2024
- Press Release Jul 31 2024
- Press Release Jul 23 2024
Later from Zydus Lifesciences
- Zydus receives final approval from USFDA for Scopolamine Transdermal System 1 mg/3 days
- Press Release Sep 10 2024
- Press Release Sep 13 2024
- Press Release Sep 27 2024
- Press Release Sep 28 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences